The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...

The FDA has approved a supplemental new drug application for the treatment of cardiomyopathy wild-type or hereditary ...

Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...

An acute necrotising myopathy is a distinct form of uncommon muscle disease characterised by the rapid advancement of ...

Interactive Tool Harnesses Real-World Data to Visualize Burden of Disease in HCM and Advance Equitable Access to Care ...

Ninerafaxstat improves cardiac energetics, cardiac reserve capacity, 6-minute walk distance and heartfailure-related health status (KCCQ) in ...

as a treatment for patients diagnosed with Duchenne muscular dystrophy ("DMD") cardiomyopathy. The FDA granted the BLA Priority Review with a Prescription Drug User Fee Act ("PDUFA") target action ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

Alnylam (ALNY) announced the FDA approval of the supplemental New Drug Application for its RNAi therapeutic, Amvuttra, for the treatment of the ...

CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.

Lexeo Therapeutics, Inc.’s LXEO share price has dipped by 10.14%, which has investors questioning if this is right time to ...